OpenIndependentCenter14 hr. agoThe European Commission has authorized the first oral formulation of Wegovy, a GLP-1 receptor agonist drug containing semaglutide, specifically for weight management. This new pill will be available in the second half of 2026 and is intended for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) who have at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea. The medication must be used alongside a calorie-restricted diet and increased physical activity. Unlike the injectable form, which requires weekly administration, the oral version needs to be taken daily under strict conditions. The approval is based on results from the Phase 3 OASIS 4 trial published in the New England Journal of Medicine, where participants lost an average of 17% of their body weight over 64 weeks.
Bias read (Center): The article presents factual information about the regulatory approval of a pharmaceutical product without overtly promoting or criticizing any political stance. It provides balanced reporting on the medical implications, usage guidelines, and scientific basis for the drug’s approval, without taking
Il GiornaleParty-alignedCenter15 hr. agoThe European Commission has approved the sale of Wegovy, the first oral pill for weight loss, developed by Novo Nordisk. The drug, containing 25 mg of semaglutide, is taken once daily and is intended for individuals with obesity or overweight who have at least one weight-related comorbidity. Clinical trials showed that, combined with a healthy lifestyle, Wegovy led to an average weight loss of around 17%, compared to 3% with a placebo. Approximately one-third of participants achieved a weight loss of 20% or more. The medication is well-tolerated, with side effects similar to those of the placebo. It was previously approved in the United States, the UK, the UAE, and Bahrain.
Bias read (Center): The article provides factual information about a new medical treatment, including clinical trial results, dosage, and regulatory approvals. There is no evident ideological framing, loaded language, or biased emphasis. The content remains neutral and informative.
Italy
